These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29755611)

  • 21. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease.
    Lee JE; Cho KH; Song SK; Kim HJ; Lee HS; Sohn YH; Lee PH
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):7-16. PubMed ID: 23828835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
    Cao L; Wang HF; Tan L; Sun FR; Tan MS; Tan CC; Jiang T; Yu JT; Tan L;
    Oncotarget; 2016 Mar; 7(12):13319-27. PubMed ID: 26950278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal Resting-State Functional Connectivity Strength in Mild Cognitive Impairment and Its Conversion to Alzheimer's Disease.
    Li Y; Wang X; Li Y; Sun Y; Sheng C; Li H; Li X; Yu Y; Chen G; Hu X; Jing B; Wang D; Li K; Jessen F; Xia M; Han Y
    Neural Plast; 2016; 2016():4680972. PubMed ID: 26843991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal Changes in Functional Brain Connectivity Predicts Conversion to Alzheimer's Disease.
    Serra L; Cercignani M; Mastropasqua C; Torso M; Spanò B; Makovac E; Viola V; Giulietti G; Marra C; Caltagirone C; Bozzali M
    J Alzheimers Dis; 2016; 51(2):377-89. PubMed ID: 26890769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal Study of Impaired Intra- and Inter-Network Brain Connectivity in Subjects at High Risk for Alzheimer's Disease.
    Zhan Y; Ma J; Alexander-Bloch AF; Xu K; Cui Y; Feng Q; Jiang T; Liu Y;
    J Alzheimers Dis; 2016 Apr; 52(3):913-27. PubMed ID: 27060962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of feature representations in MRI-based MCI-to-AD conversion prediction.
    Gómez-Sancho M; Tohka J; Gómez-Verdejo V;
    Magn Reson Imaging; 2018 Jul; 50():84-95. PubMed ID: 29530541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiated Effective Connectivity Patterns of the Executive Control Network in Progressive MCI: A Potential Biomarker for Predicting AD.
    Cai S; Peng Y; Chong T; Zhang Y; von Deneen KM; Huang L;
    Curr Alzheimer Res; 2017; 14(9):937-950. PubMed ID: 28290245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.
    Pagani M; De Carli F; Morbelli S; Öberg J; Chincarini A; Frisoni GB; Galluzzi S; Perneczky R; Drzezga A; van Berckel BN; Ossenkoppele R; Didic M; Guedj E; Brugnolo A; Picco A; Arnaldi D; Ferrara M; Buschiazzo A; Sambuceti G; Nobili F
    Neuroimage Clin; 2015; 7():34-42. PubMed ID: 25610765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying Mild Cognitive Impairment with Random Forest by Integrating Multiple MRI Morphological Metrics.
    Ma Z; Jing B; Li Y; Yan H; Li Z; Ma X; Zhuo Z; Wei L; Li H;
    J Alzheimers Dis; 2020; 73(3):991-1002. PubMed ID: 31884464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer's disease.
    Hänggi J; Streffer J; Jäncke L; Hock C
    J Alzheimers Dis; 2011; 26(4):719-34. PubMed ID: 21709375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease.
    Tondelli M; Wilcock GK; Nichelli P; De Jager CA; Jenkinson M; Zamboni G
    Neurobiol Aging; 2012 Apr; 33(4):825.e25-36. PubMed ID: 21782287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large intracranial volume accelerates conversion to dementia in males and APOE4 non-carriers with mild cognitive impairment.
    An H; Son SJ; Cho S; Cho EY; Choi B; Kim SY;
    Int Psychogeriatr; 2016 May; 28(5):769-78. PubMed ID: 26674540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of advanced machine learning methods on resting-state fMRI network for identification of mild cognitive impairment and Alzheimer's disease.
    Khazaee A; Ebrahimzadeh A; Babajani-Feremi A
    Brain Imaging Behav; 2016 Sep; 10(3):799-817. PubMed ID: 26363784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer's disease.
    Schmitter D; Roche A; Maréchal B; Ribes D; Abdulkadir A; Bach-Cuadra M; Daducci A; Granziera C; Klöppel S; Maeder P; Meuli R; Krueger G;
    Neuroimage Clin; 2015; 7():7-17. PubMed ID: 25429357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discerning mild cognitive impairment and Alzheimer Disease from normal aging: morphologic characterization based on univariate and multivariate models.
    Liao W; Long X; Jiang C; Diao Y; Liu X; Zheng H; Zhang L;
    Acad Radiol; 2014 May; 21(5):597-604. PubMed ID: 24433704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Grey-matter atrophy in Alzheimer's disease is asymmetric but not lateralized.
    Derflinger S; Sorg C; Gaser C; Myers N; Arsic M; Kurz A; Zimmer C; Wohlschläger A; Mühlau M
    J Alzheimers Dis; 2011; 25(2):347-57. PubMed ID: 21422522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.